Literature DB >> 1510375

Iron and oxygen radicals in brain.

J M Gutteridge1.   

Abstract

The brain has been shown to contain regions with high concentrations of non-heme iron, and some of this iron can be chelated, which suggests that it is in a low molecular mass form. The chelatable iron appears to be responsible for the in vitro peroxidation of homogenized brain tissue lipids. It has been suggested that low molecular mass iron is essential for normal brain functions, and that iron is present in the reduced ferrous state. Recent studies have shown that chelatable iron is often present in micromolar concentrations in apparently normal cerebrospinal fluids (CSF), and that this iron is often increased in certain neurological diseases. Using a molecular recognition assay, based on the in vitro degradation of DNA by bleomycin and chelated ferrous ions, it has been possible to conclude that the low molecular mass iron present in CSF is also in the reduced ferrous state. Ferrous ions are able to transfer electrons to molecular oxygen to form reactive and damaging intermediates of oxygen, some of which are free radicals. Increased levels of iron in brain tissue or CSF, however, are not necessarily synonymous with increased activation of oxygen. Detailed studies of brain iron deposits in neurological diseases are long overdue, and require new and pioneering methodologies to approach the problem.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510375     DOI: 10.1002/ana.410320705

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

Review 1.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

3.  Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias.

Authors:  Shino Magaki; Ravi Raghavan; Claudius Mueller; Kerby C Oberg; Harry V Vinters; Wolff M Kirsch
Journal:  Neurosci Lett       Date:  2007-03-03       Impact factor: 3.046

4.  Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy.

Authors:  Xiaoling Deng; Ruben Vidal; Ella W Englander
Journal:  Neurosci Lett       Date:  2010-05-15       Impact factor: 3.046

Review 5.  Role of iron in ischemia-induced neurodegeneration: mechanisms and insights.

Authors:  Gillipsie Minhas; Shweta Modgil; Akshay Anand
Journal:  Metab Brain Dis       Date:  2014-03-11       Impact factor: 3.584

Review 6.  Aging in the glomerulus.

Authors:  Jocelyn E Wiggins
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-07-25       Impact factor: 6.053

7.  Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study.

Authors:  Geeta S M Ramsaransing; Sanne A Mellema; Jacques De Keyser
Journal:  Nutr J       Date:  2009-08-10       Impact factor: 3.271

8.  Apotransferrin-induced recovery after hypoxic/ischaemic injury on myelination.

Authors:  Mariano Guardia Clausi; Laura A Pasquini; Eduardo F Soto; Juana M Pasquini
Journal:  ASN Neuro       Date:  2010-11-19       Impact factor: 4.146

9.  Elevated metals compromise repair of oxidative DNA damage via the base excision repair pathway: implications of pathologic iron overload in the brain on integrity of neuronal DNA.

Authors:  Hui Li; Rafal Swiercz; Ella W Englander
Journal:  J Neurochem       Date:  2009-07-08       Impact factor: 5.372

10.  Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Kyota Fujita; Toshihiro Seike; Noriko Yutsudo; Mizuki Ohno; Hidetaka Yamada; Hiroo Yamaguchi; Kunihiko Sakumi; Yukiko Yamakawa; Mizuho A Kido; Atsushi Takaki; Toshihiko Katafuchi; Yoshinori Tanaka; Yusaku Nakabeppu; Mami Noda
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.